Technical Analysis for VCNX - Vaccinex, Inc.

Grade	Last Price	% Change	Price Change
	6.35	1.60%	0.10

VCNX closed up 1.6 percent on Wednesday, April 24, 2019, on 1.12 times normal volume.

ADX	Long-Term	Intermediate-Term	Short-Term
Strong	N/A	Up	Up
See historical VCNX trend table...

Date	Alert Name	Type	% Chg
Apr 24	20 DMA Support	Bullish	0.00%
Apr 24	Inside Day	Range Contraction	0.00%
Apr 24	Wide Bands	Range Expansion	0.00%
Apr 24	Up 3 Days in a Row	Strength	0.00%
Apr 23	Crossed Above 20 DMA	Bullish	1.60%
Apr 23	Stochastic Buy Signal	Bullish	1.60%
Apr 23	Wide Bands	Range Expansion	1.60%
Apr 23	Oversold Stochastic	Weakness	1.60%
Apr 22	Narrow Range Bar	Range Contraction	15.45%
Apr 22	NR7	Range Contraction	15.45%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Vaccinex Inc. is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics. The Company is focused on providing treatments for serious diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It provides SEMA4D antibody platform, which is focused on developing its lead product candidate VX15/2503 (VX15) for the treatment of non-small cell lung cancer, NSCLC, osteosarcoma, melanoma and Huntington’s disease. It also provides ActiveMAb antibody discovery platform, a human antibody discovery platform used for expressing large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of vaccinia, a mammalian virus. Its product candidate VX5 is in preclinical development for the treatment of multiple sclerosis and potentially for other autoimmune disorders.
Health Biotechnology Cancer Biology Immunology Antibodies Immune System Monoclonal Antibodies Non Small Cell Lung Cancer Multiple Sclerosis Antibody Melanoma Serious Diseases Autoimmune Disorders Neurodegenerative Diseases Treatment Of Non Small Cell Lung Cancer Osteosarcoma Treatment Of Multiple Sclerosis Nsclc Seth Lederman Tolerx

Indicator	Bull Case	Neutral / Hold	Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary:	Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

Date	Title
Apr 15	Midday movers and shakers
Apr 15	Fibrocell Science leads healthcare gainers; Conatus Pharmaceuticals and Aphria among the losers
Apr 9	Vaccinex, Inc. Summary of Key Data Presented at the 2019 Annual Meeting of the American Association for Cancer Research (AACR)
Apr 8	54 Biggest Movers From Friday
Apr 2	Healthcare names dominate midday movers
Apr 1	Vaccinex up 26% on AACR presentations
Apr 1	Vaccinex, Inc. to Provide Clinical Data on Posters Presented at the 2019 Annual Meeting of the American Association for Cancer Research (AACR)
Mar 13	Vaccinex, Inc. to Present at the Oppenheimer & Co. 29th Annual Healthcare Conference on March 19, 2019
Mar 13	Vaccinex reports FY results
Mar 13	Vaccinex Reports Fourth Quarter 2018 Financial Results and Provides Corporate Update

Pivot Point Level	Traditional / Classic	Fibonacci	Demark	Woodie	Camarilla
Resistance 4 (R4)					7.13
Resistance 3 (R3)	7.12	6.85			7.00
Resistance 2 (R2)	6.85	6.65		6.86	6.96
Resistance 1 (R1)	6.60	6.53	6.73	6.61	6.91
Pivot Point	6.33	6.33	6.39	6.34	6.33
Support 1 (S1)	6.08	6.13	6.21	6.09	5.79
Support 2 (S2)	5.81	6.01		5.82	5.74
Support 3 (S3)	5.56	5.81			5.70
Support 4 (S4)					5.57